Full-Time
Senior Director
Trade & Distribution
Posted on 8/18/2026
Replimune Group
201-500 employees
Develops oncolytic viral immunotherapies for cancer
No salary listed
Woburn, MA, USA
Hybrid
Remote candidates living beyond 65 miles of Woburn must travel to the Woburn headquarters every 4–6 weeks or as business needs require.
Bachelor's, Master's, MBA
 Operations & Logistics (1) |
|---|
Get referred to Replimune Group
See people who can refer or advise you
- A bachelor's degree is required; an advanced degree is preferred.
- At least 15 years of biotech or pharmaceutical experience, including 5 years managing third-party logistics, specialty distributor/specialty pharmacy, and group purchasing organization vendors.
- Extensive experience distributing oncology buy-and-bill and special-handling therapeutic products.
- Advanced analytical skills related to trade and distribution service performance reporting.
- Proficiency in Microsoft Word, PowerPoint, and Excel.
- Deep understanding of performance and operational indicators of success.
- Demonstrated experience forecasting and managing vendor budgets.
- Strong background in pharmaceutical data platforms.
- Exemplary presentation skills for internal and external executive engagement.
- Demonstrated negotiation skills and ability to make sound business arguments to influence internal and external decision-makers.
- Extensive communication and collaboration skills, with the ability to drive consensus.
- Ability to thrive in a fast-paced startup environment with high expectations and accountability for deliverable quality and timing.
- Willingness to undertake responsibilities outside the individual's area of expertise.
- Experience influencing internal stakeholders and external parties.
- Lead decision-making on company and product distribution strategy, partner selection, required data fields and reports, distribution-partner contracting, system monitoring, and inventory management.
- Manage accounts, monitor performance, set business rules, and conduct contracting activities for all Trade and Distribution vendors.
- Hire and train account directors who are employees or vendors to support Trade and Distribution strategy and execution.
- Develop and conduct routine business reviews using vendor data to report launch metrics and measure operational performance of contracted Trade and Distribution vendors.
- Oversee the timely and accurate collection, analysis, management, and dissemination of distribution data and convert analytics into actionable insights.
- Serve as a point of contact for the optimal customer experience and address service gaps when necessary.
- Collaborate with Sales, Marketing, Operations, Supply Chain, Information Technology, CMC, Finance, Medical Affairs, Legal, and Compliance to identify and monitor Trade and Distribution deliverables.
- Assist in managing Market Access data, contract-performance metrics, and chargebacks to support accurate revenue recognition.
- Develop and manage operational budgets consistent with corporate financial goals.
- Ensure compliance with corporate policies and procedures and United States healthcare laws and regulations.
- Undertake various responsibilities outside the individual's area of expertise as opportunities arise.
- An advanced degree, including an MBA, is preferred.
Replimune develops cancer therapies that use engineered viruses (oncolytic immunotherapies) to attack tumors. These treatments selectively infect cancer cells, causing their destruction, and at the same time stimulate the immune system to recognize and fight tumors. By combining multiple methods of action, Replimune aims to boost the effectiveness of existing immune checkpoint inhibitors and create a stronger anti-tumor response. The company focuses on research, development, and clinical testing, and plans to earn revenue through partnerships, licensing, and eventual sales of approved therapies. Its goal is to deliver workable cancer treatments by validating safety and efficacy in clinical trials and bringing these therapies to patients with various cancers.
Company Size
201-500
Company Stage
IPO
Headquarters
Woburn, Massachusetts
Founded
2015
Get referred to Replimune Group
See people who can refer or advise you
Simplify's Take
What believers are saying
- Replimune raised about $150 million on August 11, 2026 for launch.
- Michelle DiNapoli joined as chief commercial officer on August 18, 2026.
- Analysts expect TUDRIQEV shipments within 60 days, unlocking first revenue.
What critics are saying
- A D.Mass. securities class action alleges Replimune hid FDA study-design defects.
- Confirmatory IGNYTE-3 data are expected in 2030; failure triggers withdrawal risk.
- Bristol Myers and Merck dominate melanoma, squeezing access and physician adoption.
What makes Replimune Group unique
- TUDRIQEV won FDA accelerated approval on August 6, 2026, after two rejections.
- RP1 uses an engineered HSV-1 platform to stimulate injected and distant tumors.
- Replimune pairs oncolytic immunotherapy with nivolumab, targeting post-PD-1 melanoma failures.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Performance Bonus
Company Equity
Growth & Insights and Company News
6 month growth
↑ 11%1 year growth
↑ 14%2 year growth
↑ 17%Replimune hires Genentech veteran to lead melanoma launch. Replimune has installed a former Genentech executive as chief commercial officer days after an accelerated approval for its melanoma therapy, while Neumora's Paul Berns hands off the CEO title. Replimune named Michelle DiNapoli, a former Genentech executive, as chief commercial officer effective Aug. 18, weeks after winning a new accelerated approval for its melanoma therapy; REPL traded at 14.57, up 3.70%, as of 13:51 GMT on Aug. 21, 2026. Replimune (REPL) has hired Michelle DiNapoli as chief commercial officer, effective Aug. 18, filling the most consequential open seat at a company that has just cleared the hardest hurdle in its history: a new accelerated approval for its melanoma therapy. DiNapoli arrives from a career that includes time at Genentech, one of the industry's deepest benches for oncology commercial talent. The timing is the message. Companies do not recruit a commercial chief for an abstraction. They recruit one when there is a label to sell against, a payer conversation to open, and a field force to stand up before revenue is expected to appear. Replimune's approval was hard-fought - the phrasing used by Endpoints News in reporting the appointment - and a hard-fought approval usually leaves a narrower label and a more sceptical prescribing audience than a clean first-pass clearance would. What a chief commercial officer actually has to build. For a first-launch oncology company, the commercial chief owns four things that all have to land in roughly the same quarter. First, pricing and gross-to-net: the list price, the discounts negotiated with payers and group purchasing organisations, and the patient-assistance structure that determines what the company actually collects. Second, market access - getting the product onto payer formularies and, for a physician-administered therapy, into hospital and infusion-centre buying processes, which is a separate and slower fight than a retail pharmacy listing. Third, the field organisation: sales representatives, medical science liaisons and reimbursement specialists who help oncology practices navigate coding and coverage. Fourth, distribution - specialty pharmacy or specialty distributor relationships, and cold-chain logistics where the product demands it. Each of those has a lead time measured in months, which is why the hire lands before the launch rather than after it. A Genentech background is a specific signal here. Genentech's commercial model in oncology has historically been built around deep account-level engagement with academic cancer centres and large community oncology networks, rather than breadth-first primary-care selling. That is the right muscle memory for a novel melanoma therapy, where the initial prescribing base is likely to be concentrated in a relatively small number of high-volume centres. Accelerated approval sets the clock, not just the label. Accelerated approval is a conditional pathway. The Food and Drug Administration grants it on the basis of an endpoint judged reasonably likely to predict clinical benefit, on the understanding that the sponsor will complete confirmatory work. That creates a dual obligation for Replimune: commercialise now, and continue generating the evidence that keeps the approval in place. The commercial consequence is that pricing and access decisions get made under a cloud of conditionality. Payers know the approval is provisional and can price that risk into coverage policy - prior authorisation requirements, step edits, restrictions to the exact patient population in the label. A commercial chief with large-cap oncology experience is precisely the profile a board recruits to argue against those restrictions from the first payer meeting rather than the third. For investors, the practical question is not whether the approval happened but how quickly it converts. Watch for the first disclosed net revenue quarter, the number of ordering accounts, and any management commentary on gross-to-net erosion. Those are the metrics that separate an approval from a franchise. The share price is off the mat, not out of the woods. REPL changed hands at 14.57 as of 13:51 GMT on Aug. 21, 2026, up 3.70% on the day from a previous close of 14.05, with an intraday range of 13.81 to 14.67. That is a firmer move than the broad market managed on the same session: the S&P 500 tracker SPY was at $765.08, up 0.33%, the Nasdaq 100 proxy QQQ at $711.88, up 0.13%, and the Dow tracker DIA at $530.70, up 0.60%. Outperforming the index on the day of a commercial-hire announcement is not, by itself, a verdict on the therapy. Small-cap biotech trades on narrative velocity, and a credible senior hire is a low-cost, high-visibility signal that management believes there is something worth selling. The harder test comes when the company has to put a number next to it. Neumora's Berns steps back from the CEO title. Outperforming the index on the day of a commercial-hire announcement is not, by itself, a verdict on the therapy. Separately, Paul Berns is shedding the chief executive title at Neumora (NMRA). The shares traded at 1.54 as of 13:51 GMT on Aug. 21, 2026, up 1.65% from a previous close of 1.51, in a day range of 1.51 to 1.56. A share price at that level tells its own story about where the market has put the company. Sub-$2 biotech equities typically reflect a combination of clinical disappointment, financing pressure, or both, and a change at the top is the standard corporate response. Whether Berns's departure from the CEO role represents a planned handover or a board-driven reset is not something the disclosure settles. What matters operationally is continuity of the pipeline and the balance sheet. Leadership changes at small biotechs frequently precede a strategic review - a reprioritisation of programmes, a partnering push, or in harder cases a sale or wind-down. Shareholders should look for whether the successor is an internal promotion, which usually signals continuity, or an external appointment with turnaround credentials, which usually does not. Two companies, two points on the same curve. Set side by side, Replimune and Neumora illustrate the two directions a clinical-stage biotech can travel. One has cleared the regulator and is now spending on the apparatus of selling - a commercial chief, and behind that title a payroll of field staff, market-access specialists and distribution contracts that did not exist a year ago. The other is changing its leader with the market valuing it in low single digits per share. The connective tissue is that both moves are, at bottom, about credibility with capital. Replimune is signalling that the approval is real enough to build a company around. Neumora is signalling that the current configuration needs changing. In a sector where funding conditions have punished companies without a clear path to revenue, the personnel page has become a leading indicator that investors read as closely as the clinical one. The next disclosures to watch are Replimune's first commentary on launch metrics and pricing, and Neumora's naming of who takes the chief executive role and on what mandate. Key facts. * REPL price: 14.57, +3.70% as of 13:51 GMT, Aug. 21, 2026 * New hire: Michelle DiNapoli, chief commercial officer, effective Aug. 18 * NMRA price: 1.54, +1.65% as of 13:51 GMT, Aug. 21, 2026 * Leadership change: Neumora's Paul Berns sheds the CEO title Frequently asked questions. Who is Replimune's new chief commercial officer? Michelle DiNapoli, whose appointment took effect Aug. 18. She previously worked at Genentech, a company with one of the industry's deepest oncology commercial organisations. Her mandate at Replimune is to build the pricing, market-access, field-force and distribution apparatus needed to launch the company's newly approved melanoma therapy. What does accelerated approval mean for Replimune? Accelerated approval is a conditional US pathway in which the FDA clears a drug on an endpoint reasonably likely to predict clinical benefit, with the sponsor obliged to complete confirmatory work. It allows commercial sales to begin sooner but leaves the approval provisional, which payers can factor into coverage restrictions and prior-authorisation requirements. How did Replimune shares trade on the day of the announcement? REPL traded at 14.57 as of 13:51 GMT on Aug. 21, 2026, up 3.70% from a previous close of 14.05, within an intraday range of 13.81 to 14.67. That outpaced the broad market that session, with the S&P 500 tracker up 0.33% and the Nasdaq 100 proxy up 0.13%. What is happening at Neumora? Paul Berns is giving up the chief executive title at Neumora. The company's shares traded at 1.54 as of 13:51 GMT on Aug. 21, 2026, up 1.65% from a previous close of 1.51. The disclosure does not settle whether the change is a planned handover or a board-driven reset. Why do biotechs hire a commercial chief before launch? Because the work has long lead times. Setting list price and negotiating discounts, securing payer formulary placement, recruiting a specialised field organisation and arranging specialty distribution each take months. A company that waits until the product is available to start that work forfeits early revenue and cedes ground to competing therapies. What should investors watch next at Replimune? The first quarter in which net product revenue is disclosed, the number of ordering accounts or treating centres, management commentary on gross-to-net discounting, and progress on the confirmatory evidence required to convert the accelerated approval into a full one. Those metrics, not the approval itself, determine whether a launch becomes a franchise.
Replimune Group announced FDA accelerated approval of TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who progressed on PD-1 antibody treatment. The commercial stage biotechnology company expects to launch the product within 60 days. The company recently completed a $150 million financing to support the commercial launch and ongoing IGNYTE-3 confirmatory trial. Replimune appointed Michelle DiNapoli as chief commercial officer, effective 18 August 2026. DiNapoli brings over 25 years of biopharmaceutical experience, including seven years at Deciphera Pharmaceuticals where she built the US sales force and led commercial operations. The approval represents a milestone for the company as it transitions to a fully integrated biotechnology firm.
Replimune Group (NASDAQ:REPL) CAO sells 7,632 shares. August 12, 2026 Key points. * Replimune CAO Andrew Schwendenman sold 7,632 shares at an average price of $12.97, generating about $98,987. The filing said the sale was made to cover tax-withholding obligations after equity awards vested, and he retained 99,425 shares. * Replimune shares recently traded at $15.24, near the company's 52-week high of $15.68, with a market capitalization of approximately $1.28 billion. However, the company reported a quarterly loss of $0.76 per share, missing analyst estimates of a $0.66 loss. * The company priced a $150 million public offering to fund development of its oncology pipeline and RP1, while analysts have generally turned more positive on the stock. Replimune also faces securities-class-action allegations concerning disclosures about RP1, adding legal and reputational uncertainty. * Five stocks we like better than Replimune Group. Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) CAO Andrew Schwendenman sold 7,632 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $98,987.04. Following the transaction, the chief accounting officer owned 99,425 shares of the company's stock, valued at $1,289,542.25. This represents a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Replimune Group stock performance. NASDAQ:REPL traded up $1.59 during mid-day trading on Wednesday, hitting $15.24. The company's stock had a trading volume of 8,269,132 shares, compared to its average volume of 5,046,735. The business's fifty day moving average is $10.34 and its two-hundred day moving average is $7.64. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -4.51 and a beta of 0.88. The company has a debt-to-equity ratio of 0.63, a current ratio of 4.79 and a quick ratio of 4.79. Replimune Group, Inc. has a 1 year low of $1.50 and a 1 year high of $15.68. Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings data on Monday, June 29th. The company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.10). Analysts anticipate that Replimune Group, Inc. will post -2.45 EPS for the current fiscal year. More Replimune Group news. Here are the key news stories impacting Replimune Group this week: * Positive Sentiment: $150 million offering priced: Replimune priced a $150 million underwritten public offering, providing additional cash to support development of its oncology pipeline and RP1. The financing appears to have reassured investors about the company's liquidity and ability to fund operations. Replimune Announces Pricing of $150 Million Underwritten Offering * Neutral Sentiment: Insider transactions were primarily tax-related: CEO Sushil Patel, CFO Emily Hill, CAO Andrew Schwendenman and insider Konstantinos Xynos sold shares totaling approximately $1.01 million. The filings state that the sales covered tax-withholding obligations tied to vested equity awards, while each executive retained a substantial position; therefore, the transactions provide limited evidence of a change in business confidence. SEC insider transaction filing * Negative Sentiment: Several law firms publicized a securities class action: The lawsuits cover investors who purchased Replimune securities between October 20, 2025, and April 10, 2026. The allegations claim the company misled investors about the efficacy and commercial viability of RP1 and failed to disclose unresolved FDA study-design concerns. CEO Sushil Patel and CFO Emily Hill are named as individual defendants, and the lead-plaintiff deadline is October 5, 2026. The notices increase legal and reputational uncertainty, although the allegations have not been proven. REPL Class Action Reminder Levi and Korsinsky class action notice Analyst upgrades and downgrades. Several equities research analysts have commented on the company. JPMorgan Chase & Co. upped their price objective on Replimune Group from $17.00 to $20.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th. Weiss Ratings cut shares of Replimune Group from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday. Leerink Partners raised shares of Replimune Group from a "market perform" rating to an "outperform" rating and increased their price target for the stock from $11.00 to $17.00 in a report on Tuesday, August 4th. BMO Capital Markets upgraded shares of Replimune Group from an "underperform" rating to an "outperform" rating and set a $16.00 price target on the stock in a research report on Tuesday, June 30th. Finally, Piper Sandler raised shares of Replimune Group from a "hold" rating to a "strong-buy" rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $11.86. Discover more EV market analysis Market cap calculator Institutional trading of Replimune Group. A number of institutional investors and hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Replimune Group by 17.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company's stock valued at $435,000 after buying an additional 6,653 shares in the last quarter. Millennium Management LLC increased its holdings in Replimune Group by 2.8% in the 1st quarter. Millennium Management LLC now owns 1,223,236 shares of the company's stock worth $11,927,000 after acquiring an additional 33,574 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Replimune Group by 20.9% during the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company's stock worth $6,729,000 after acquiring an additional 119,145 shares during the period. Rhumbline Advisers raised its position in Replimune Group by 6.9% during the second quarter. Rhumbline Advisers now owns 102,005 shares of the company's stock worth $948,000 after acquiring an additional 6,616 shares during the period. Finally, Sei Investments Co. lifted its holdings in Replimune Group by 149.5% during the second quarter. Sei Investments Co. now owns 30,478 shares of the company's stock valued at $283,000 after purchasing an additional 18,263 shares in the last quarter. 92.53% of the stock is currently owned by hedge funds and other institutional investors. Replimune Group company profile. Replimune Group, Inc is a clinical-stage biotechnology company focused on developing next-generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary "RP" platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses. Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Replimune Group, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list. While Replimune Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain - combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
REPL investors have opportunity to lead Replimune Group, Inc. securities fraud lawsuit with SBS law. LOS ANGELES, Aug. 11, 2026 (GLOBE NEWSWIRE) - Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: October 20, 2025 to April 10, 2026 DEADLINE: October 5, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Replimune failed to address study design concerns the FDA had previously communicated about its Biologics License Application ("BLA"). The Company submitted data from an unplanned analysis of the RP1-104 study to the FDA which included only 10% of the planned study enrollment. Due to these actions, the FDA was likely to reject the Company's BLA. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Replimune, investors suffered damages. We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected]. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor. Schall, Brown & Schwartz LLP Brian Schall, Esq., Andrew Brown, Esq., David Schwartz, Esq., www.schallfirm.com Office: 310-301-3335 [email protected] Schall, Brown & Schwartz LLP
Replimune Group, a commercial-stage biotechnology company, announced the pricing of an underwritten offering of approximately 9.7 million shares of common stock at $12.06 per share. The company is also offering pre-funded warrants to purchase roughly 2.7 million shares at $12.0599 per warrant to certain investors. The aggregate gross proceeds from the offering are expected to be approximately $150 million, before deducting underwriting discounts and other expenses. The offering is expected to close on 11 August 2026, subject to customary closing conditions. Leerink Partners, J.P. Morgan, and Cantor are acting as bookrunning managers for the offering. Replimune, headquartered in Massachusetts, focuses on developing oncolytic immunotherapies for cancer treatment.